Study Summary
This is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with MRD+ B-ALL
Interested in this trial?
Submit an InquiryInterventions
ThisCART19ABIOLOGICAL
ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The first affiliated hospital of medical college of zhejiang university | Hangzhou | Zhejiang | China |